The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…
TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, but competing biologics such as IL-17 inhibitors (Cosentyx, Taltz), IL-12/23…
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. Key treatment goals…
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
In the last two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen/Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have transformed the…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that…